Matricellular Protein CCN5 Reverses Established Cardiac Fibrosis

Journal of the American College of Cardiology

Volumn 67, Issue 13, 2016, Pages 1556-1568

  Jeong, Dongtak ^a   Yang, Dong Kwon ^a   Kho, Changwon ^a   Oh, Jae Gyun ^a   Lee, Ahyoung ^a   Chen, Jiqiu ^a   Liang, Lifan ^a   Mitsuyama, Shinichi ^a   D'Escamard, Valentina ^a   Kovacic, Jason C ^a   Hajjar, Roger J ^a   Lee, Min Ah ^b   Li, Yan ^b   Hong, Gyeongdeok ^b   Song, Min Ho ^b   Park, Woo Jin ^b   LaRocca, Thomas J ^c   Kwak, Tae Hwan ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Gwangju Institute of Science and Technology (GIST)   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Chungnam National University   (South Korea)

Author keywords

apoptosis; gene therapy; heart failure; NF B

Indexed keywords

CCN5 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CCN PROTEIN; REPRESSOR PROTEIN; WISP2 PROTEIN, HUMAN;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIAC MUSCLE CELL; CELL TRANSDIFFERENTIATION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; HEART FAILURE; HEART MUSCLE FIBROSIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CARDIAC MUSCLE; DEPENDOPARVOVIRUS; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSIS; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; CCN INTERCELLULAR SIGNALING PROTEINS; CELL TRANSDIFFERENTIATION; DEPENDOVIRUS; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROSIS; GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; HUMANS; MICE, TRANSGENIC; MYOCARDIUM; MYOFIBROBLASTS; REPRESSOR PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84976364301     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.01.030     Document Type: Article

References (30)

1. 1 Houser, S.R., Margulies, K.B., Is depressed myocyte contractility centrally involved in heart failure?. Circ Res 92 (2003), 350–358.
2. 2 Konstam, M.A., Kramer, D.G., Patel, A.R., et al. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. J Am Coll Cardiol Img 4 (2011), 98–108.
3. 3 Wong, T.C., Piehler, K., Meier, C.G., et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation 126 (2012), 1206–1216.
4. 4 Schelbert, E.B., Fonarow, G.C., Bonow, R.O., et al. Therapeutic targets in heart failure: refocusing on the myocardial interstitium. J Am Coll Cardiol 63 (2014), 2188–2198.
5. 5 Dzeshka, M.S., Lip, G.Y., Snezhitskiy, V., et al. Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications. J Am Coll Cardiol 66 (2015), 943–959.
6. 6 Wong, T.C., Piehler, K.M., Kang, I.A., et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 35 (2014), 657–664.
7. 7 López, B., González, A., Ravassa, S., et al. Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol 65 (2015), 2449–2456.
8. 8 Thum, T., Gross, C., Fiedler, J., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456 (2008), 980–984.
9. 9 Weidemann, F., Herrmann, S., Störk, S., et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 120 (2009), 577–584.
10. 10 Gulati, A., Jabbour, A., Ismail, T.F., et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309 (2013), 896–908.
11. 11 Izawa, H., Murohara, T., Nagata, K., et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112 (2005), 2940–2945.
12. 12 Tomasek, J.J., Gabbiani, G., Hinz, B., et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3 (2002), 349–363.
13. 13 Souders, C.A., Bowers, S.L., Baudino, T.A., Cardiac fibroblast: the renaissance cell. Circ Res 105 (2009), 1164–1176.
14. 14 Zeisberg, E.M., Tarnavski, O., Zeisberg, M., et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13 (2007), 952–961.
15. 15 Chu, P.Y., Mariani, J., Finch, S., et al. Bone marrow-derived cells contribute to fibrosis in the chronically failing heart. Am J Pathol 176 (2010), 1735–1742.
16. 16 Holbourn, K.P., Acharya, K.R., Perbal, B., The CCN family of proteins: structure-function relationships. Trends Biochem Sci 33 (2008), 461–473.
17. 17 Chen, M.M., Lam, A., Abraham, J.A., et al. CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 32 (2000), 1805–1819.
18. 18 Yoon, P.O., Lee, M.A., Cha, H., et al. The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis. J Mol Cell Cardiol 49 (2010), 294–303.
19. 19 Song, J.J., Aswad, R., Kanaan, R.A., et al. Connective tissue growth factor (CTGF) acts as a downstream mediator of TGF-beta1 to induce mesenchymal cell condensation. J Cell Physiol 210 (2007), 398–410.
20. 20 Kagan, H.M., Li, W., Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 88 (2003), 660–672.
21. 21 Widyantoro, B., Emoto, N., Nakayama, K., et al. Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 121 (2010), 2407–2418.
22. 22 Dobaczewski, M., Bujak, M., Li, N., et al. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ Res 107 (2010), 418–428.
23. 23 Petrov, V.V., Fagard, R.H., Lijnen, P.J., Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 39 (2002), 258–263.
24. 24 Elmore, S., Apoptosis: a review of programmed cell death. Toxicol Pathol 35 (2007), 495–516.
25. 25 Lipson, K.E., Wong, C., Teng, Y., et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair, 5(Suppl 1), 2012, S24.
26. 26 Brilla, C.G., Funck, R.C., Rupp, H., Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102 (2000), 1388–1393.
27. 27 Díez, J., Querejeta, R., López, B., et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105 (2002), 2512–2517.
28. 28 Kovacic, J.C., Mercader, N., Torres, M., et al. Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition: from cardiovascular development to disease. Circulation 125 (2012), 1795–1808.
29. 1. Am J Respir Cell Mol Biol 21 (1999), 658–665.
30. 30 Turner, N.A., Porter, K.E., Regulation of myocardial matrix metalloproteinase expression and activity by cardiac fibroblasts. IUBMB Life 64 (2012), 143–150.